|Table of Contents|

Clinical analysis of oxaliplatin and tegafur in the treatment of middle and advanced hepatocellular carcinoma after radiofrequency ablation and its effect on serum CXCL13,LTBP2

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2021 04
Page:
640-645
Research Field:
Publishing date:

Info

Title:
Clinical analysis of oxaliplatin and tegafur in the treatment of middle and advanced hepatocellular carcinoma after radiofrequency ablation and its effect on serum CXCL13,LTBP2
Author(s):
CHEN Jie; LAI Zhao; QING Xiaosong; ZHAO Bin
Department of Hepatobiliary Surgery,the Forth People's Hospital of Zigong,Sichuan Zigong 643000,China.
Keywords:
advanced hepatocellular carcinoma; radiofrequency ablation; oxaliplatin; tegafur
PACS:
R735.7
DOI:
10.3969/j.issn.1672-4992.2021.04.020
Abstract:
Objective：To investigate clinical effect of oxaliplatin and tegafur in the treatment of middle and advanced liver cancer after radiofrequency ablation and the influence on serum CXCL13 and LTBP2.Methods:A total of 80 advanced hepatocellular carcinoma patients in our hospital from March 2015 to July 2016 were randomly divided into observation group or control group,40 cases in each group.Patients in the control group were treated with radiofrequency ablation combined with oxaliplatin.Patients in the observation group were treated with radiofrequency ablation,and oxaliplatin combined with tegafur was given after surgery.The clinical efficacy and postoperative tumor ablation rate of the two groups of patients was observed and compared.The levels of serum chemokines CXCL13 and potential transforming growth factor binding protein 2 (LTBP2) were measured by enzyme-linked immunosorbent assay (ELISA).The quality of life of cancer patients developed according to the European Cancer Research and Treatment System was determined.The Quality of Life Questionnaire (QLQ-C30) in the table system assessed the quality of life of patients before and after surgery.The incidence of adverse reactions in both groups was recorded.Results:There was no significant difference in postoperative tumor elimination rate between the two groups (P=0.556).The effective rate of treatment in the observation group (75.00%) was significantly higher than that in the control group (52.50%).The difference was statistically significant (P=0.036).Before treatment,there was no significant difference in serum CXCL13 and LTBP2 expression between the two groups (P＞0.05).After treatment,serum CXCL13 and LTBP2 levels were significantly lower than those before treatment,and the observation group was significant.The level of physical function,role function,social function,emotional function,cognitive function and overall quality of life score after treatment was significantly higher than that before treatment (P＜0.05)，and observation group was higher than the control group (P＜0.05).There was no significant difference in adverse reaction rates between the two groups (25.00% vs 30.00%,P=0.617).The incidence of lung cancer recurrence and metastasis in the observation group was significantly lower than that in the control group (P＜0.05).Conclusion:After radiofrequency ablation,oxaliplatin and tigeol can effectively treat middle and advanced liver cancer,improve the quality of life,inhibit tumor recurrence and metastasis,reduce serum CXCL13 and LTBP2 levels,and improve long-term survival rate.

References:

［1］张爽,王锋,孟庆玲.原发性肝癌患者流行病学与乙型肝炎病毒感染调查［J］.中国疫苗和免疫,2018,24(02):133-136，151. ZHANG S,WANG F,MENG QL.Epidemiology of hepatitis B virus infection among primary liver cancer patients ［J］.Chinese Journal of Vaccines and Immunization,2018,24(02):133-136，151.
［2］黄乾荣,张玲.原发性肝癌治疗研究新进展［J］.实用医学杂志,2016,32(14):2275-2278. HUANG GR,ZHANG L.New progress in the treatment of primary liver cancer ［J］.The Journal of Practical Medicine,2016,32(14):2275-2278.
［3］樊嘉,周俭,杨欣荣.精准医学时代的肝癌外科治疗［J］.中华消化外科杂志,2017,16(1):22-27. FAN J,ZHOU J,YANG XR.Surgical treatment of hepatocellular carcinoma in the precision medicine era［J］.Chinese Journal of Digestive Surgery,2017,16(1):22-27.
［4］冯凯,马宽生,别平.射频消融技术在肝癌综合治疗中合理应用 ［J］.中国实用外科杂志,2016,36(6):621-623. FENG K,MA KS,BIE P.Rational application of radiofrequency ablation in the radical cure for hepatocellular carcinoma［J］.Chinese Journal of Practical Surgery,2016,36(6):621-623.
［5］曾文胜,张阳德.奥沙利铂对人肝癌HepG2细胞周期、凋亡及侵袭能力的影响［J］.中国现代医学杂志,2011,21(14):1565-1567. ZENG WS,ZHENG YD.Effect of Oxaliplatin on cell cycle,apoptosis and invasion ability of human hepatoma cell line HepG2［J］.China Journal of Modern Medicine,2011,21(14):1565-1567.
［6］李建旺,黄春珍,元建华.索拉非尼联合替吉奥治疗晚期肝癌的临床观察［J］.中国现代医学杂志,2016,26(24):77-82. LI JW,HUANG CZ,YUAN JH,et al.Clinical study of Sorafenib combined with S-1 in advanced hepatocellular carcinoma ［J］.China Journal of Modern Medicine,2016,26(24):77-82.
［7］王鹏,张玮,孙光志.奥沙利铂联合替吉奥胶囊治疗晚期原发性肝癌的疗效观察［J］.泰州职业技术学院学报,2017,17(05):52-55. WANG P,ZHANG W,SUN GZ.Observe the curative effect of oxaliplatin combined with S-1 capsule in the treatment of primary carcinoma of liver ［J］.Journal of Taizhou Polytechnical College,2017,17(05):52-55.
［8］董志超.原发性肝癌患者血清CXCL13和IL-31检测的临床意义探讨［J］.实用肝脏病杂志,2017,20(06):779-780. DONG ZC.Serum chemokine CXCL13 and IL-31 in diagnosis of patients with primary liver cancer ［J］.Journal of Practical Hepatology,2017,20(06):779-780.
［9］王盼攀,张水军,郭文治,等.肝细胞肝癌患者血清转化生长因子结合蛋白2的表达及临床意义［J］.中华实验外科杂志,2016,33(1):215-217. WANG PP,ZHANG SJ,GUO WZ,et al.Expression of serum latent transforming growth factor-β binding protein 2 in patients with hepatocellular carcinoma and its clinical significance［J］.Chinese Journal of Experimental Surgery,2016,33(1):215-217.
［10］KAMARAJAH SK,FRANKEL TL,SONNENDAY C,et al.Critical evaluation of the American Joint Commission on Cancer (AJCC) 8th edition staging system for patients with hepatocellular carcinoma (HCC):A Surveillance,Epidemiology,End Results (SEER) analysis ［J］.Journal of Surgical Oncology,2018,117(4):644-650.
［11］朱楠,鲁东,肖景坤.肝动脉化疗栓塞联合射频消融术治疗中晚期肝癌的疗效［J］.中国介入影像与治疗学,2017,14(4):195-199. ZHU N,LU D,XIAO JK.Efficacy of transcatheter arterial chemoembolization combined with radiofrequency ablation in advanced hepatocellular carcinoma patients［J］.Chinese Journal of Interventional Imaging and Therapy,2017,14(4):195-199.
［12］中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)［J］.传染病信息,2017,16(3):705-720. Health and Family Planning Commission of the People's Republic of China.Diagnosis,management,and treatment of hepatocellular carcinoma (V2017)［J］.Chinese Journal of Hepatology,2017,16(3):705-720.
［13］赵芳,张钧,祝英乔.超声造影与增强CT评价肝癌射频消融疗效的研究［J］.中国超声医学杂志,2006,22(2):125-127. ZHAO F,ZHANG J,ZHU YQ.Study on therapeutic effect of hepatic carcinoma with radiofrequency ablation by enhanced ultrasonography and CT［J］.Chinese Journal of Ultrasound in Medicine，2006,22(2):125-127.
［14］RONOT M,BOUATTOUR M,WASSERMANN J,et al.Alternative Response Criteria (Choi,European association for the study of the liver,and modified Response Evaluation Criteria in Solid Tumors ［RECIST］) versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib ［J］.The Oncologist,2014,19(4):394-402.
［15］SNYDER CF,BLACKFORD AL,SUSSMAN J,et al.Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients' supportive care needs ［J］.Quality of Life Research,2015,24(5):1207-1216.
［16］郭武华,张吉翔.肝癌综合治疗的现状［J］.世界华人消化杂志,2008,16(20):2199-2203. GUO WH,ZHANG JX.Current status of comprehensive treatment of liver cancer［J］.World Chinese Journal of Digestion,2008,16(20):2199-2203.
［17］谢晓燕,吕明德,殷晓煜.超声引导经皮射频消融治疗肝癌的研究［J］.中华外科杂志,2003,41(1):23-26. XIE XY,LYU MD,YIN XY.Ultrasound-guided percutaneous radiofrequency ablation for liver cancer［J］.Chinese Journal of Surgery,2003,41(1):23-26.
［18］王锋,秦叔逵,华海清.含奥沙利铂化疗方案治疗对索拉非尼耐药的晚期原发性肝癌的临床观察［J］.临床肿瘤学杂志,2014,19(03):226-230. WANG F,QIN SK,HUA HQ.Clinical observation of oxaliplatin-based regimen for sorafenib-resistant advanced primary liver carcinoma［J］.Chinese Clinical Oncology,2014,19(03):226-230.
［19］苏惠婷,李冰,曹炬，等.CXCL13、IL-31在原发性肝癌患者血清中的表达及临床意义［J］.中国免疫学杂志,2016,32(11):1682-1688. SU HT,LI B,CAO J,et al.Expression and significance of CXCL13 and IL-31 in serum of patients with primary hepatic carcinoma［J］.Chinese Journal of Immunology,2016,32(11):1682-1688.
［20］吴福道,张小静,蔡辉.替吉奥联合奥沙利铂治疗晚期胃癌的临床疗效观察［J］.重庆医学,2015,44(13):1835-1837. WU FD,ZHANG XJ,CAI H.Clinical efficacy of tigeol combined with oxaliplatin in the treatment of advanced gastric cancer ［J］.Chongqing Medicine,2015,44(13):1835-1837.

Memo

Memo:
-
Last Update: 1900-01-01